Pfizer (PFE) Total Debt (2009 - 2025)

Pfizer has disclosed Total Debt across 17 years of filings, most recently posting $64.8 billion for FY2025.

• In Q1 2026, Total Debt rose 3.78% year-over-year to $64.5 billion; the TTM figure through Mar 2026 stood at $64.5 billion (up 3.78% YoY), while the FY2025 annual figure was $64.8 billion, up 1.33% from the prior year.
• Total Debt climbed to $64.8 billion in FY2025, from $63.9 billion in the prior year.
• Over the last five years, Total Debt for PFE reached as high as $71.9 billion in FY2023 and fell as low as $35.8 billion in FY2022.
• The 5-year median for Total Debt is $63.9 billion (2024), against an average of $54.6 billion.
• Annual changes were most pronounced in 2021 — Total Debt plunged 36.85% — and 2023, when it surged 100.64%.
• A 5-year view of Total Debt shows it stood at $38.2 billion in 2021, then dropped by 6.31% to $35.8 billion in 2022, then surged by 100.64% to $71.9 billion in 2023, then fell by 11.05% to $63.9 billion in 2024, then advanced by 1.33% to $64.8 billion in 2025.
• According to Business Quant data, Total Debt over the past three periods registered $64.8 billion, $63.9 billion, and $67.7 billion for FY2025, FY2024, and FY2024 respectively.